BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 9112486)

  • 1. Treatment of advanced renal cell carcinoma with a combination of human lymphoblastoid interferon-alpha and cimetidine.
    Kinouchi T; Saiki S; Maeda O; Kuroda M; Usami M; Kotake T
    J Urol; 1997 May; 157(5):1604-7. PubMed ID: 9112486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of advanced renal cell carcinoma with a combination of human lymphoblastoid interferon-alpha and cimetidine.
    Kinouchi T; Meguro N; Maeda O; Saiki S; Kuroda M; Usami M; Kotake T
    Int J Urol; 1996 Jan; 3(1 Suppl):S41-3. PubMed ID: 24304021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of metastatic renal cell carcinoma with a combination of human lymphoblastoid interferon-alpha and cimetidine.
    Kotake T; Kinouchi T; Saiki S; Kuroda M; Miki T; Kiyohara H; Usami M
    Jpn J Clin Oncol; 1991 Feb; 21(1):46-51. PubMed ID: 2067120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.
    Clark PE; Hall MC; Miller A; Ridenhour KP; Stindt D; Lovato JF; Patton SE; Brinkley W; Das S; Torti FM
    Urology; 2004 Jun; 63(6):1061-5. PubMed ID: 15183950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-modal treatment of primarily using continuous subcutaneous interferon-alpha injection in combination with surgery and/or radiotherapy.
    Maruoka M; Fujimura M; Kawamura K; Suzuki S; Hamano M; Nishikawa Y; Nagayama T
    Int J Urol; 2005 May; 12(5):442-8. PubMed ID: 15948742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Successful management for advanced renal cell carcinoma under combination therapy with human lymphoblastoid interferon-alpha and UFT (mixture of tegafur and uracil): a case report].
    Kanno H; Kitami K; Senga Y; Takahashi T; Nagashima Y
    Hinyokika Kiyo; 1993 Aug; 39(8):725-9. PubMed ID: 8379474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors for renal cell carcinoma with tumor thrombus extension.
    Klatte T; Pantuck AJ; Riggs SB; Kleid MD; Shuch B; Zomorodian N; Kabbinavar FF; Belldegrun AS
    J Urol; 2007 Oct; 178(4 Pt 1):1189-95; discussion 1195. PubMed ID: 17698087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
    Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
    J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Management of advanced renal cell carcinoma: surgical treatment of metastasis].
    Kinouchi T; Kotake T
    Hinyokika Kiyo; 1994 Oct; 40(10):919-24. PubMed ID: 7992709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
    Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Successful preoperative interferon-alpha therapy of advanced renal cell carcinoma with tumor thrombus extending into the inferior vena cava: a case report].
    Kato T; Madono K; Saito J; Kakuta Y; Tanigawa G; Yazawa K; Hosomi M; Ito K
    Hinyokika Kiyo; 2008 Feb; 54(2):119-22. PubMed ID: 18323170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
    Ryan CW; Vogelzang NJ; Dumas MC; Kuzel T; Stadler WM
    Cancer; 2000 Mar; 88(6):1317-24. PubMed ID: 10717612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective study of combined treatment with interferon-alpha and active vitamin D3 for Japanese patients with metastatic renal cell carcinoma.
    Obara W; Mizutani Y; Oyama C; Akaza H; Ishii N; Kohri K; Namiki M; Okuyama A; Shima H; Yokoyama M; Shuin T; Miki T; Watanabe Y; Fujioka T
    Int J Urol; 2008 Sep; 15(9):794-9. PubMed ID: 18651865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
    Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup.
    Haferkamp A; Bastian PJ; Jakobi H; Pritsch M; Pfitzenmaier J; Albers P; Hallscheidt P; Müller SC; Hohenfellner M
    J Urol; 2007 May; 177(5):1703-8. PubMed ID: 17437789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.
    Gez E; Rubinov R; Gaitini D; Meretyk S; Best LA; Native O; Stein A; Erlich N; Beny A; Zidan J; Haim N; Kuten A
    Cancer; 2002 Oct; 95(8):1644-9. PubMed ID: 12365011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies.
    Belldegrun AS; Klatte T; Shuch B; LaRochelle JC; Miller DC; Said JW; Riggs SB; Zomorodian N; Kabbinavar FF; Dekernion JB; Pantuck AJ
    Cancer; 2008 Nov; 113(9):2457-63. PubMed ID: 18823034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase-II trial of combination treatment of interferon-α, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma.
    Tatokoro M; Fujii Y; Kawakami S; Saito K; Koga F; Matsuoka Y; Iimura Y; Masuda H; Kihara K
    Cancer Sci; 2011 Jan; 102(1):137-43. PubMed ID: 20973869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials.
    Schwartz LH; Mazumdar M; Wang L; Smith A; Marion S; Panicek DM; Motzer RJ
    Cancer; 2003 Oct; 98(8):1611-9. PubMed ID: 14534876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.